Long-term safety of KarXT in adults with bipolar I mania
Studies the long-term safety of KarXT in adults with bipolar I mania.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Key facts
- Where
- Ancona, Genoa, Milan, Pisa, and Siena, ItalySee the 5 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06929273, who can take part
Where in Italy
- Azienda Ospedaliero-Universitaria delle MarcheAncona, ItalyTaking people
- IRCCS Azienda Ospedaliera MetropolitanaGenoa, ItalyTaking people
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Azienda Ospedaliero Universitaria PisanaPisa, ItalyTaking people
- Azienda Ospedaliero Universitaria SeneseSiena, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06929273EU 2024-520259-26-00
- Record updated
- 26 October 2026
- Original description
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I)Read full original descriptionShow less
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I)
The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
Inclusion: Participants who participated in double-blind placebo-controlled study (CN0120036, CN0120037, or CN0120046):; Participants must have completed treatment period of parent study; De novo participants who did not participate in double-blind placebo-controlled studies:; Participants must have primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI, v7.0.2), with symptoms of mania or mixed mania; Participants must have Young Mania Rating Scale (YMRS) score of ≥ 14 at Screening and at baseline; Participants must have CGI-BP score of ≥ 3 at Screening and at baseline; Participants does not require hospitalization for acute mania.
Exclusion: De novo participants who did not participate in double-blind placebo-controlled studies:; Participants must not have primary diagnosis of BP-I with rapid cycling (ie, ≥ 4 distinct mood episodes in one year); Participants must not have any primary DSM-5-TR disorder other than BP-I with mania or mania with mixed features within 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), including BP-I with depression, (previous 3 months only), Bipolar-II disorder, major depressive disorder, borderline personality disorder, and primary psychotic disorder, with the exception of mild anxiety disorders; Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), or current use as determined by urine toxicology screen or alcohol test; Participants must not have history of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months; Participants must not have history or high risk of urinary retention, gastric retention, or untreated narrow-angle glaucoma; All participants:; All participants with a risk for suicidal behavior at baseline as determined by Investigator's clinical assessment or history of suicidal behavior as assessed on C-SSRS; Participants who participated in double-blind placebo-controlled study (CN0120036, CN0120037, or CN0120046):; Discontinuation from any KarXT parent studies; Other protocol-defined Inclusion/Exclusion criteria apply.